Nivolumab-induced sensory ganglionopathy

Basit Öğe Kaydı
dc.authoridSahin, Hasan/0000-0002-6699-8278
dc.contributor.authorCoskun, Ozlem
dc.contributor.authorSahin, Hasan
dc.contributor.authorYalcin, Selim
dc.contributor.authorSahin, Yekta C.
dc.contributor.authorCoskun, Ugur
dc.date.accessioned2025-01-21T16:42:53Z
dc.date.available2025-01-21T16:42:53Z
dc.date.issued2023
dc.departmentKırıkkale Üniversitesi
dc.description.abstractIntroduction Nivolumab is s a human monoclonal antibody. Due to its widespread use in many cancers, including Merkel cell carcinoma, adverse reactions associated with nivolumab, such as neuropathies, endocrinopathies, gastrointestinal problems, and skin toxicities have been increasing. Sensory ganlionopathy is rarely observed in these patients. Case description We present a 63-year-old male with a medical history of Merkel cell carcinoma that recurred two times in the inguinal region. After undergoing surgery with adjuvant radiotherapy, a second surgery was performed. The patient suffered from tingling in all four limbs plus difficulty in walking after initiation of the third dose of nivolumab. Management and outcome After 1 month of 1 mg/kg/day methylprednisolone treatment, he showed significant improvement. Subsequently, the systemic corticosteroid regimen was tapered to 5 mg every other day. The treatment resulted in significant improvement in all extremities. Discussion Sensory ganlionopathy can be seen as a side effect of an immune checkpoint inhibitor, even though it is very extraordinary. This is the case in the literature to develop sensory ganlionopathy due to nivolumab. We believe that patients using nivolumab may develop sensory ganlionopathy and management should be taken on this point.
dc.identifier.doi10.1177/10781552231177712
dc.identifier.endpage1515
dc.identifier.issn1078-1552
dc.identifier.issn1477-092X
dc.identifier.issue6
dc.identifier.pmid37254496
dc.identifier.scopus2-s2.0-85162979348
dc.identifier.scopusqualityQ3
dc.identifier.startpage1510
dc.identifier.urihttps://doi.org/10.1177/10781552231177712
dc.identifier.urihttps://hdl.handle.net/20.500.12587/25161
dc.identifier.volume29
dc.identifier.wosWOS:001078086300001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSage Publications Ltd
dc.relation.ispartofJournal of Oncology Pharmacy Practice
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20241229
dc.subjectNivolumab; ganglionopathy; case report; Merkel cell carcinoma; side effect
dc.titleNivolumab-induced sensory ganglionopathy
dc.typeArticle

Dosyalar

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu